Table 1 The relationship between CRTAC1 expression and clinicopathological parameters in individuals diagnosed with NSCLC.
From: CRTAC1 identified as a promising diagnosis and prognostic biomarker in lung adenocarcinoma
Characteristics | Low expression of CRTAC1 | High expression of CRTAC1 | P value |
|---|---|---|---|
n | 520 | 521 | |
Pathologic T stage, n (%) | 0.001 | ||
T1 | 118 (11.4%) | 172 (16.6%) | |
T2 | 307 (29.6%) | 279 (26.9%) | |
T3 | 69 (6.6%) | 51 (4.9%) | |
T4 | 25 (2.4%) | 17 (1.6%) | |
Pathologic N stage, n (%) | 0.012 | ||
N0 | 319 (31.3%) | 351 (34.4%) | |
N1&N2&N3 | 195 (19.1%) | 154 (15.1%) | |
Pathologic M stage, n (%) | 0.466 | ||
M0 | 391 (48.3%) | 386 (47.7%) | |
M1 | 14 (1.7%) | 18 (2.2%) | |
Pathologic stage, n (%) | 0.003 | ||
Stage I | 246 (23.9%) | 295 (28.7%) | |
Stage II | 166 (16.1%) | 121 (11.8%) | |
Stage III & Stage IV | 104 (10.1%) | 97 (9.4%) | |
Age, n (%) | 0.243 | ||
< = 65 | 233 (23%) | 215 (21.2%) | |
> 65 | 273 (26.9%) | 292 (28.8%) | |
Gender, n (%) | 0.004 | ||
Male | 333 (32%) | 288 (27.7%) | |
Female | 187 (18%) | 233 (22.4%) |
